Ibezapolstat

Acurx Pharmaceuticals reported Q3 2024 results, highlighting ibezapolstat's Phase 2 trial success for C. difficile infection, a new patent, and FDA meeting plans for Phase 3 trials. Financials show a net loss of $2.8M, with $5.8M cash on hand. R&D expenses slightly decreased to $1.2M.

Acurx Pharmaceuticals presented Phase 2 trial results of ibezapolstat at IDWeek 2024, showing comparable safety and cure rates to vancomycin with gut microbiome benefits. The company plans international Phase 3 trials and regulatory submissions in the EU, UK, Japan, and Canada. Ibezapolstat received FDA QIDP and Fast-Track Designation for C. difficile Infection treatment.

Acurx Pharmaceuticals' ibezapolstat shows promise in treating Gram-positive bacteria without cross resistance, with potential for Clostridioides difficile and anthrax. Despite a 50% stock decline, analysts predict a 500% upside.

Acurx Pharmaceuticals' ACXP shares dropped after Phase 2 trial results. The trial for ibezapolstat, targeting C. difficile Infection, showed a 96% clinical cure rate with no safety concerns. Despite challenges like COVID-19 impacting enrollment, the company plans Phase 3 trials, citing ibezapolstat's competitive advantages.